Addex Therapeutics (ADXN) Upgraded by Zacks Investment Research to Hold

Addex Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Addex Therapeutics Upgraded by Zacks Investment Research on 10-11-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Addex Therapeutics (ADXN) Upgraded by Zacks Investment Research to Hold